0001104659-23-042156.txt : 20230405
0001104659-23-042156.hdr.sgml : 20230405
20230405160726
ACCESSION NUMBER: 0001104659-23-042156
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230403
FILED AS OF DATE: 20230405
DATE AS OF CHANGE: 20230405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SAPIRSTEIN JAMES
CENTRAL INDEX KEY: 0001559509
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37853
FILM NUMBER: 23802566
MAIL ADDRESS:
STREET 1: 1517 SAN JACINTO
CITY: HOUSTON
STATE: TX
ZIP: 77002
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: First Wave BioPharma, Inc.
CENTRAL INDEX KEY: 0001604191
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464993860
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 YAMATO ROAD
STREET 2: SUITE 502
CITY: BOCA RATON
STATE: FL
ZIP: 33431
BUSINESS PHONE: 561-589-7020
MAIL ADDRESS:
STREET 1: 777 YAMATO ROAD
STREET 2: SUITE 502
CITY: BOCA RATON
STATE: FL
ZIP: 33431
FORMER COMPANY:
FORMER CONFORMED NAME: AzurRx BioPharma, Inc.
DATE OF NAME CHANGE: 20141103
FORMER COMPANY:
FORMER CONFORMED NAME: BioPharma d'Azur, Inc.
DATE OF NAME CHANGE: 20140331
4
1
tm2311820-1_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-04-03
0
0001604191
First Wave BioPharma, Inc.
FWBI
0001559509
SAPIRSTEIN JAMES
C/O FIRST WAVE BIOPHARMA, INC
777 YAMATO ROAD, SUITE 502
BOCA RATON
FL
33431
1
1
0
0
President and CEO
0
Common Stock
2023-04-03
4
S
0
3347
2.50
D
39510
D
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.41 to $2.60. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Includes unvested RSUs.
All amounts reflect the 1:7 reverse stock split effective as of January 18, 2023.
/s/ James Sapirstein
2023-04-05